Allopurinol News and Research

RSS
Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

FDA accepts Regeneron's ARCALYST sBLA for review

FDA accepts Regeneron's ARCALYST sBLA for review

New results from BioCryst's BCX4208 Phase 2b gout study

New results from BioCryst's BCX4208 Phase 2b gout study

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

Ardea Biosciences reports positive outcome from lesinurad End-of-Phase 2 meetings with FDA

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

Metabolex commences arhalofenate Phase 2 clinical trial for treatment of hyperuricemia and gout

BioCryst's BCX4208 study results in gout to be presented at EULAR meeting

BioCryst's BCX4208 study results in gout to be presented at EULAR meeting

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Ardea Biosciences fourth quarter net loss decreases to $0.6 million

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

BioCryst reports net loss of $9.1M for fourth quarter 2010 vs. $15.2M net income for fourth quarter 2009

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

BioCryst commences BCX4208/allopurinol combination Phase 2b study in gout patients

BioCryst commences BCX4208/allopurinol combination Phase 2b study in gout patients

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Study demonstrates preventive effect of urate lowering therapy on cardiovascular mortality

Study demonstrates preventive effect of urate lowering therapy on cardiovascular mortality

BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

Study finds anti-gout medication may reduce risk of colorectal cancer

Study finds anti-gout medication may reduce risk of colorectal cancer

Caffeine intake increases risk for recurrent gout attacks

Caffeine intake increases risk for recurrent gout attacks